Board summary
Key figures
48,269
Registered population
55.7% aged 18–64
24.8%
Aged 65+
ICB 18.8% · England 17.9%
14.1%
Ethnic minority (non-White)
7.2% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 0.8% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
8,252
Hypertension register
+2.94% in 3 yrs · England +5.60%
375
SMI register
32.6% of Reigate and Banstead's
743
COPD register
Reviews +5.45% in 3 yrs
Forecast to 2030
8,947
Hypertension patients, 2030
+695 on today
59.4%
QRISK ≥20% on statins, 2030
+0.46pp over 3 yrs
7.0%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England and ICB.
Only 57.1% of asthma patients had an annual review (England 65.7%, ICB 65.6%), leaving about 1,200 of 2,843 registered patients unreviewed.
High-risk lipid therapy lags national rates.
Lipid therapy for QRISK ≥ 20% is 58.5% (England 63.6%, 3-year change +0.8% vs +6.2%) and 63.7% in CKD (England 70.3%).
Overall hypertension and diabetes control exceed England.
Hypertension treatment to threshold is 73.6% (England 70.3%) and non-frail diabetes HbA1c control is 64.4% (England 57.4%), though 80+ BP control trails at 77.9%.
Population, age and ethnicity
With 24.8% aged 65+, an older population structure shapes primary care demand
Across 48,269 registered patients, 24.8% (11,986) are aged 65+, above Reigate and Banstead (19.4%), NHS Surrey Heartlands ICB (18.8%) and England (17.9%). Working-age adults (18–64) make up 55.7% (26,899), below the borough (59.6%), ICB (60.8%) and England (62.7%), with 19.4% (9,384) aged 0–17. Census estimates show an 85.9% White population (borough 84.4%, ICB 85.3%, England 81.1%) and a 14.1% ethnic minority share, with Asian residents at 7.2% (England 9.6%). Projected list growth to 2030 is 1.9% (unverified methodology). Ethnicity reflects Census usual residents, not registered patients.
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Reigate and Banstead local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Reigate and Banstead LA) | 2,154 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 87.6% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 64.4% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Reigate and Banstead LA) | 991 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Reigate and Banstead LA) | 8.9 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile is 8.7 and all five practices record 0.0% Core20
Banstead Healthcare PCN has an average IMD decile of 8.7, against 8.0 in Reigate and Banstead, 7.9 in the ICB and 5.5 in England. Across all five practices, 0.0% of registered patients live in Core20 deciles 1 and 2, against 1.1% in the borough, 0.8% in the ICB and 21.0% in England. Practice IMD deciles range from 8.1 at Tadworth Medical Centre to 9.1 at Longcroft Clinic. With zero Core20 patients, health inequality work could focus on clinical inclusion groups rather than neighbourhood outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
375
SMI register
0.77% recorded prevalence
229
Learning disability register
0.47% recorded prevalence
33
Care homes, 1,286 beds
In the PCN catchment
7.9%
Provide unpaid care
Reigate and Banstead, Census 2021
The PCN records 229 patients on the learning disability register (0.5% vs borough 0.6%, England 0.6%) and 375 on the severe mental illness register (0.8% vs England 1.0%), alongside 33 catchment care homes (1,286 beds; occupancy unmeasured). Lower crude recorded prevalence does not establish under-detection; clinical audits would test whether identification gaps exist.
Severe mental illness: physical health checks
Recorded SMI checks reach 89.4% for BP (England 83.4%) and 87.9% for BMI (England 82.1%). However, BMI recording fell 2.4 pp over three years (England +5.1 pp), pointing to emerging gaps in routine physical health monitoring.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,252
Hypertension register
+2.94%
Register growth, 3 yrs
Reigate and Banstead +4.55% · England +5.60%
+1.66pp
BP control, under 80
≤140/90 · −1.36pp aged 80+
+695
More patients by 2030
Forecast 8,947 (18.00%)
Hypertension case-finding and control
Banstead Healthcare PCN records hypertension prevalence of 17.0% (8,252 patients), above Reigate and Banstead (14.0%), NHS Surrey Heartlands Integrated Care Board (14.3%) and England (15.2%). Blood pressure control under age 80 is 71.8% (England 67.8%), but control in patients aged 80 and over trails at 77.9% versus England's 81.2%, falling 1.7% over three years (England +2.2%). Hypertension blood pressure recording reached 88.2% (England 90.0%). Lower control in patients aged 80 and over than national benchmarks warrants prioritising clinical review and medication titration for older hypertensive cohorts.
Lipids and statins
For patients with QRISK ≥ 20%, lipid-lowering therapy uptake is 58.5%, trailing Reigate and Banstead (59.3%), NHS Surrey Heartlands Integrated Care Board (59.4%) and England (63.6%). CKD lipid therapy uptake is 63.7% (England 70.3%). Fewer at-risk cardiovascular patients receive lipid-lowering therapy than England rates imply, prioritising a systematic recall audit for high-risk cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 66,853 | £2.20 | £2.24 | £1.86 | £147,077 |
| Cardiovascular (all), 2025 | 93,909 | £4.54 | £4.74 | £3.33 | £426,347 |
In 2025, lipid-modifying drug spend was £121,877 across 55,907 items at £2.18 per item, matching NHS Surrey Heartlands Integrated Care Board (£2.18) but above Reigate and Banstead (£2.11) and England (£1.82), costing £20,127 more than at England's unit cost. Higher unit costs than England suggest reviewing lipid-modifying prescribing choices alongside local formulary guidance to balance spend and treatment reach.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+3.43%
Asthma reviews, PCN 3-yr change
+4.44%
Asthma reviews, England
+6.17%
Asthma prevalence, PCN
Asthma prevalence is 6.2% (England 6.6%), with three-year register growth of +6.2% (England +0.5%). However, only 57.1% of asthma patients received an annual review, trailing the borough (59.8%), ICB (65.6%) and England (65.7%), leaving an estimated shortfall of about 1,200 of 2,843 patients unreviewed. Second-hand smoke status recording for ages 6–19 also lags at 74.5% (England 78.8%). Conversely, COPD reviews reach 82.2% (England 76.4%), suggesting review recall systems exist but leave a substantial unreviewed asthma cohort.
Cancer register and children's immunisation
Cancer prevalence is 5.5% (2,696 patients), exceeding England (3.8%), consistent with the PCN's older demographic. In childhood immunisation, 6-in-1 uptake reaches 97.9% at 12 months, exceeding the 95.0% target. However, in separate age 5 cohorts, MMR dose 2 is 87.5% and the 4-in-1 booster is 85.7%, both trailing the 95.0% benchmark. This suggests pre-school booster recall requires structured follow-up across primary care.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, 61.4% of staged cancers in NHS Surrey Heartlands ICB were diagnosed at stage 1 or 2 (2,955 of 4,810), exceeding England (55.3%) by 6.1 percentage points but sitting 13.6 pp below the 75.0% national ambition by 2028. Known-stage share was 67.7% (4,810 of 7,106 registered cancers). Bowel was 48.1% (26.9 pp below ambition) and lung 33.2% (41.8 pp below ambition). Reaching 75.0% requires about 650 (652.5) extra early-stage diagnoses annually across the ICB (system data, not PCN level). Cervical screening reached 73.3% across the PCN (England 66.8%), spanning 68.0% at Heathcote Medical Centre to 70.8% at Tadworth Medical Centre.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Epsom and St Helier University Hospitals NHS Trust met all three cancer waiting standards: 62-day referral to treatment at 86.8% (standard 85.0%), 28-day faster diagnosis at 89.7% (standard 75.0%) and 31-day combined treatment at 99.2% (standard 96.0%). Conversely, NHS Surrey and Sussex Integrated Care Board achieved 71.5% on 62-day waits (13.5 pp below standard; England 71.2%), Surrey and Sussex Healthcare NHS Trust reached 70.0% and Croydon Health Services NHS Trust 69.9%. Diagnostic six-week waits at Epsom and St Helier were 1.1% for CT and 0.3% for MRI.
| Pathways within standard (%) | Epsom and St Helier | Surrey and Sussex Healthcare | Croydon Health | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 89.70 | 77.74 | 83.22 | 79.29 | 79.32 |
| 31-day treatment (96%) | 99.16 | 96.20 | 99.06 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 86.82 | 69.97 | 69.88 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Epsom and St Helier | Surrey and Sussex Healthcare | Croydon Health | England |
|---|---|---|---|---|
| MRI | 0.31 | 27.53 | 0.26 | 21.40 |
| CT | 1.06 | 18.49 | 7.69 | 9.92 |
| Echocardiography | 25.49 | 43.78 | 3.60 | 28.48 |
| Colonoscopy | 33.01 | 15.11 | 21.80 | 30.83 |
| Gastroscopy | 30.90 | 21.06 | 17.94 | 29.02 |
| All 15 DM01 tests | 6.83 | 28.50 | 3.51 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 69.6% of community service contacts among Reigate and Banstead residents (76,215 of 109,530 contacts). This pattern is consistent with the area's older demographic profile. These figures reflect local authority resident contacts rather than registered patients, describing wider system demand rather than Banstead Healthcare PCN delivery.
Practice variation and patient experience
Practice phone access and vaccination achievement vary widely across the five member practices
In 2025/26, clinical-domain QOF achievement spanned 97.0% at Heathcote Medical Centre to 100.0% at Longcroft Clinic (England 97.1%). Conversely, vaccination and immunisation achievement diverged by 56.0 pp, from 27.6% at Tadworth Medical Centre to 83.5% at Tattenham Health Centre (England 55.2%), demonstrating internal variation across member practices.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Tattenham | 112 | 0.0 | 70.1% | 62.5% | 91.6% |
| Longcroft Clinic | 115 | 0.0 | 53.0% | 78.2% | 83.6% |
| Tadworth | 86 | 0.0 | 43.6% | 79.6% | 78.6% |
| Heathcote | 104 | 0.0 | 40.0% | 65.1% | 78.3% |
| Nork Clinic | 114 | 0.0 | 53.5% | 69.8% | 76.1% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fourteen of 25 tracked three-year trends trail England despite high recorded baseline prevalence
Fourteen of 25 tracked three-year trends trail England. Delivery lags are led by heart failure reviews, which fell 3.8% (England +8.7%), and mental health register BMI checks, which fell 2.4 pp (England +5.1 pp). High-risk lipid therapy for QRISK 20% or over rose +0.8% (England +6.2%). Conversely, relative gains outpaced England in non-frail diabetes HbA1c control (+6.4% vs England +4.4%), COPD reviews (+5.5% vs England +2.8%) and diabetes statin prescribing (+5.0% vs England +2.1%). Practice audits would test whether these delivery lags reflect recall shortfalls.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
BMI record (SMI)
QRISK statin treatment
Alcohol record (psychosis)
BP control, 80+
Diabetes statin (no CVD)
COPD reviews
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Reigate and Banstead | Asset | PCN | Reigate and Banstead |
|---|---|---|---|---|---|
| Care homes (catchment) | 33 (1,286 beds) | n/a | Schools (catchment) | 44 | n/a |
| Children's centres | 2 | 8 | Places of worship | 26 | 70 |
| Libraries | 2 | 6 | Food banks (VCS) | n/a | 6 |
| Homelessness support (VCS) | n/a | 2 | Day centres (VCS) | 14 | 40 |
| Children and young people (VCS) | n/a | 8 | Carers support groups (VCS) | 1 | 6 |
| Primary schools (LA maintained) | 5 | 14 | Primary academies | 8 | 18 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma annual review coverage is 57.1% across 2,843 registered patients, compared with Reigate and Banstead (59.8%, difference -2.7 percentage points), NHS Surrey Heartlands Integrated Care Board (65.6%, difference -8.5 percentage points) and England (65.7%, difference -8.6 percentage points), leaving about 1,200 (1,220) patients without a recorded review in the last. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Learning disability register coding audit
Recorded learning disability prevalence is 0.5% (229 patients across a 48,269 list), below Reigate and Banstead (0.6%) and England (0.6%) by 0.1 percentage points (benchmark scenario range +55 to +57). For discussion: practices could audit clinical records for uncoded learning disability diagnoses and cross-check lists where social-care data sharing exists. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 3
Heart failure register and review audit
Heart failure prevalence is 0.9% (445 patients across 48,269 registered) versus England's 1.1% (borough 0.8%; range -61 to +85), while annual reviews fell 3.8% over three years (England +8.7%). For discussion: practices could audit heart failure coding and recall processes so functional capacity assessments are recorded at annual review. Low cost, quick to run.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Age-standardised register audit (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Annual mental health physical checks (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Older hypertension clinical review (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted screening uptake review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephone triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD patients with a review in the last 12 months | Core20PLUS5 respiratory | PCN |
| Option 2 · Learning disability register coding audit (p12) | Registered population · Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 3 · Heart failure register and review audit (p12) | Registered population · Heart failure register · Heart Failure: QOF prevalence | — | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
